Parkinson's Disease Trial, Recruiting (NCT07281755)

Parkinson's Disease Trial, Recruiting NCT07281755 Sponsor: Northumbria University Condition: Parkinson's Disease

Printed from Voxsanity (voxsanity.com.au) — NCT07281755 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Parkinsons Disease

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been diagnosed with Parkinson's disease by a specialist in movement disorders, using a specific set of recognised diagnostic guidelines (known as UK brain bank criteria)
People whose Parkinson's symptoms fall within stages 1 to 3 on a standard scale used to measure how far the condition has progressed (Hoehn & Yahr stages I–III)
People who are able to travel to and attend study visits at Northumbria University in Newcastle Upon Tyne
People who are able to walk and stand without assistance for at least 2 minutes

Who may not be able to join:

People who have a history of neurological conditions other than Parkinson's disease, such as Huntington's disease, stroke, traumatic brain injury, multiple sclerosis, or Alzheimer's disease
People who score below 21 on a standard memory and thinking assessment called the Montreal Cognitive Assessment (MoCA)
People who have had an injury to their legs or feet within the past 6 weeks

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 22 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Rodrigo Vitorio, PhD, Northumbria University

Phone: 01912273343

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07281755

Sponsor: Northumbria University

Phase: Not Applicable

Status: Recruiting

Condition: Parkinson's Disease

Trial contact: 01912273343

More information: https://clinicaltrials.gov/study/NCT07281755

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been diagnosed with Parkinson's disease by a specialist in movement disorders, using a specific set of recognised diagnostic guidelines (known as UK brain bank criteria)
People whose Parkinson's symptoms fall within stages 1 to 3 on a standard scale used to measure how far the condition has progressed (Hoehn & Yahr stages I–III)
People who are able to travel to and attend study visits at Northumbria University in Newcastle Upon Tyne
People who are able to walk and stand without assistance for at least 2 minutes

Who may not be able to join:

People who have a history of neurological conditions other than Parkinson's disease, such as Huntington's disease, stroke, traumatic brain injury, multiple sclerosis, or Alzheimer's disease
People who score below 21 on a standard memory and thinking assessment called the Montreal Cognitive Assessment (MoCA)
People who have had an injury to their legs or feet within the past 6 weeks

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 22 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Northumbria University

Registry

ClinicalTrials.gov

Start date

8 August 2025

Est. completion

1 September 2027

Where this trial is recruiting

🇬🇧 United Kingdom

Primary endpoints

Stride Length; Step Time; Stride Time; Cadence; Ground Contact Time; Swing Time; Stride Velocity; Gait Velocity; Area of Ellipse; Length of Ellipse; Width of Ellipse; Total Displacement; Medio-Lateral Range; Anterior-Posterior Range

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov